Search results
Order by most recent / most popular / relevance
Results: 1-10 of 96
Definition of “innovative drug” does not include variations
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 23 2013
This is an appeal by Takeda of a decision of the Court, in which the Court upheld the decision of the Minister of Health to refuse to list Takeda’s
Eli Lilly Canada v. Novopharm Limited
- Borden Ladner Gervais LLP
- -
- Canada
- -
- August 4 2010
The Court of Appeal overturned the decision of the trial judge which held that the patent was invalid
Pfizer v. Ratiopharm
- Borden Ladner Gervais LLP
- -
- Canada
- -
- August 11 2010
The Court of Appeal dismissed Pfizer's appeal from a Trial Judge decision finding the patent at issue to be invalid
Novo Nordisk v. Cobalt
- Borden Ladner Gervais LLP
- -
- Canada
- -
- August 18 2010
The Trial Judge dismissed an application seeking to prohibit Cobalt from coming to market with its generic repaglinide product
Other IP industry news of note
- Borden Ladner Gervais LLP
- -
- Canada
- -
- August 25 2010
The amendments to the Federal Court Rules regarding expert witnesses have been published into law (starting at pg 1547
Astrazeneca v. Apotex
- Borden Ladner Gervais LLP
- -
- Canada
- -
- August 25 2010
The Court found the allegations of invalidity as to lack of sound prediction of utility and of obviousness justified and dismissed the application
Novopharm v. Pfizer
- Borden Ladner Gervais LLP
- -
- Canada
- -
- October 27 2010
Novopharm brought a motion before the Federal Court seeking confidentiality for its Notice of Allegation (NOA) in the proceeding
Novopharm v. Eli Lilly and Company
- Borden Ladner Gervais LLP
- -
- Canada
- -
- September 22 2010
Novopharm filed an ANDS with Health Canada for Novo-atomoxetine
Generic association does not have standing to challenge listing on register of innovative drugs
- Borden Ladner Gervais LLP
- -
- Canada
- -
- December 21 2010
The Canadian Generic Pharmaceutical Associate (CGPA) brought a judicial review application in respect of the listing of Avamys on the Register of Innovative Drugs (Register
Costs awarded seven years after discontinuance
- Borden Ladner Gervais LLP
- -
- Canada
- -
- December 21 2010
This decision relates to a motion brought by Bayer for an order for costs of an application brought pursuant to the Patented Medicines (Notice of Compliance) Regulations
Current Search
- Workarea - Patents
- Workarea - Healthcare
- Workarea - Litigation
- Jurisdiction - Canada
- Author - Chantal Saunders